Compare Gilead Sciences, Inc. (GILD) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Linde PLC — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Linde PLC trades at $482.59 (market cap $222.05B). The key difference: Linde PLC is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Linde PLC for 88 Days on average.
| GILD | LIN | |
|---|---|---|
Market Cap | $182.09B | $222.05B |
Volume | 4,960,247 | 2,116,440 |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $546.64 |
52-Week Low | $116.74 | $389.38 |
Typical Hold Time | 111 Days | 88 Days |
Enterprise Value | $205.15B | $245.17B |
Dividend Yield | 2.23% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
LIN trades at $481.70, down 1.68% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.50 per share, beating estimates, and raised the lower end of its 2026 guidance. Revenue growth is steady, with a net income margin of 20.43% in 2025. Analyst consensus is overwhelmingly positive, with a $557.10 price target. Support is seen near $480, while resistance lies at $486.
Outlook remains favorable due to consistent earnings beats and a record $8.1 billion project backlog. Risks include elevated valuation multiples and margin pressures from higher capital expenditures. The stock offers a dividend yield with a $1.60 payment scheduled for September 2026. Investor sentiment is buoyed by AI-related contract wins, though competition and capex increases warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
